Salud financiera de hoja de balance de Gilead Sciences

Salud financiera controles de criterios 3/6

Gilead Sciences tiene un patrimonio de accionistas total de $22.7B y una deuda total de $25.0B, lo que sitúa su ratio deuda-patrimonio en 109.8%. Sus activos y pasivos totales son $62.1B y $39.4B respectivamente. El BAIT de Gilead Sciences es de $9.8B, por lo que su ratio de cobertura de intereses es de 17.3. Tiene efectivo e inversiones a corto plazo que ascienden a $8.4B.

Información clave

144.3%

Ratio deuda-patrimonio

US$25.19b

Deuda

Ratio de cobertura de intereses	17.7x
Efectivo	US$5.52b
Patrimonio	US$17.46b
Total pasivo	US$38.84b
Activos totales	US$56.29b

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17

Recent updates

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

May 23

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($14.0B) de GILD superan a sus pasivos a corto plazo ($13.0B).

Pasivo a largo plazo: Los activos a corto plazo ($16.1B) de GILD no cubren sus pasivos a largo plazo ($28.1B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de GILD (73.1%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de GILD ha crecido de 120.3% a 147.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de GILD está bien cubierta por el flujo de caja operativo (32%).

Cobertura de intereses: Los pagos de intereses de la deuda de GILD están bien cubiertos por el BAIT (17.3x cobertura).

Salud financiera de hoja de balance de Gilead Sciences

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Recent updates

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences: Cheap For A Reason

Fourth quarter dividend increased to US$0.77

Full year 2023 earnings: EPS misses analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences: The Sky Is Not Falling

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera